Advertisement

Topics

Latest "Zinc Placebo Sickle Cell Disease" News Stories

06:40 EST 14th November 2018 | BioPortfolio

Here are the most relevant search results for "Zinc Placebo Sickle Cell Disease" found in our extensive news archives from over 250 global news sources.

More Information about Zinc Placebo Sickle Cell Disease on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Zinc Placebo Sickle Cell Disease for you to read. Along with our medical data and news we also list Zinc Placebo Sickle Cell Disease Clinical Trials, which are updated daily. BioPortfolio also has a large database of Zinc Placebo Sickle Cell Disease Companies for you to search.

Showing "Zinc Placebo Sickle Cell Disease" News Articles 1–25 of 21,000+

Wednesday 14th November 2018

Zymeworks Announces Updated Clinical Data for Novel Bispecific Antibody, ZW25, Presented at the EORTC-NCI-AACR Symposium

ZW25 Active and Well Tolerated Across Multiple HER2-expressing Tumor Types Durable Anti-Tumor Activity with Confirmed Partial Responses and Median Progression-Free Survival > Six Months 82 Percent of Heavily Pretreated Patients Experienced Disease Control Zymeworks Inc. (NYSE/TSX: ZYME), a c...


Sanofi holds China Health Road Symposium at CIIE

SHANGHAI, Nov. 14, 2018 /PRNewswire/ -- At the first China International Import Expo, Sanofi, the world's leading healthcare company, said during the China Health Road Symposium, that with Innovation, Partnership and Commitment as the three key words, it will strive to introduce the innovative drugs and vaccines exhibited at the import expo to China as early as possible. The company will collabora...

Turner Syndrome Global Clinical Trials Review, H2, 2018 [Report Updated: 28092018] Prices from USD $2500

Turner Syndrome Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report, Turner Syndrome Global Clinical Trials Review, H2, 2018" provides an overview of Turner Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Turner Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries c...


Scientists engineer DNA-encoded monoclonal antibodies targeting Zaire Ebolavirus

Study results, published online in Cell Reports, showed that DMAbs were expressed over a wide window of time and offered complete and long-term protection against lethal virus challenges. The post Scientists engineer DNA-encoded monoclonal antibodies targeting Zaire Ebolavirus appeared first on Pharmaceutical Business review.

Virion Biotherapeutics Demonstrates Preclinical Proof-of-Concept for First Therapeutic Interfering Particle Candidate in Respiratory Virus Infections

--Data presented at 6th ISIVR-AVG Conference-- --Company announces Penelope Ward joins as Chief Medical Officer-- Virion Biotherapeutics today presented in vivo data on its lead product VH244, the first candidate to emerge from its Therapeutic Interfering Particles (TIPs) biologics platform. The study results highlighted that VH244 significant...

STAT Plus: A biotech analyst’s take on the future of neuroscience, ‘solving’ the placebo effect, and not over-selling the dream

"I think ... you have to approach drug development somewhat humbly."

World Diabetes Day Prompts Diopsys to Reach Out

Diopsys helps spread diabetes awareness for WDD 2018 PINE BROOK, N.J. (PRWEB) November 14, 2018 In recognition of World Diabetes Day, Diopsys is lending its voice to the global diabetes community to help raise diabetes awareness and advocacy. The company is reaching out to help educate patients and the healthcare community about the clinical and economic impact of diabetes as well as emphasize th...

DÉVELOPPEMENT : Le cerveau cablé pour la vie

Selon les US Centers for Disease Control (CDC), environ 15% des enfants âgés de 2 à 8 ans sont diagnostiqués avec au moins un trouble mental, comportemental ou du développement. Ces troubles comprennent les difficultés d'apprentissage, d'acquisition du langage, le trouble du déficit de l'attention (TDAH), l'autisme et d'autres troubles neurologiques. Ces chercheurs ...

Voice Disorders Global Clinical Trials Review, H2, 2018 [Report Updated: 28092018] Prices from USD $2500

Voice Disorders Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report, Voice Disorders Global Clinical Trials Review, H2, 2018" provides an overview of Voice Disorders clinical trials scenario. This report provides top line data relating to the clinical trials on Voice Disorders. Report includes an overview of trial numbers and their average enrollment in top countries c...

FDA grants priority review to Tecentriq combo for triple-negative breast cancer

The FDA designation for the Tecentriq chemo combination is for TNBC patients whose condition is unresectable locally advanced or metastatic and whose disease expresses the PD-L1 protein, as The post FDA grants priority review to Tecentriq combo for triple-negative breast cancer appeared first on Pharmaceutical Business review.

Stallergenes Greer Announces U.S. FDA Approval of Pediatric Indication Extension for Oralair® Sublingual Immunotherapy Tablet for the Treatment of Grass Pollen Allergy

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181113006059/en/ Stallergenes Greer (Paris:STAGR), a biopharmaceutical company specializing in treatments for respiratory allergies, today announced that it has received approval from the U.S. Food and Drug Administration ...

A Spark Of Good News For Precision Oncology In Breast Cancer

In a trial of metastatic triple-negative breast cancer, AZD5363 significantly extended patients’ overall survival from 12.6 to 19.1 months, vs. placebo, when given with chemotherapy.

US Drug Pricing Reforms Testing Limits Of Executive Action

Congressional inaction on drug pricing legislation has meant the Trump Administration is pursuing a menu of regulatory approaches. For the...   

Tuesday 13th November 2018

Shanghai Exuma to Develop Conditionally Active CAR-T Candidates

Shanghai Exuma Biotech, a subsidiary of Florida's F1 Oncology, has been formed to develop novel CAR-T cell therapies. Exuma will hold rights to F1 Oncology's proprietary CAR-T technologies, which are combined with BioAtla's conditionally active biologic (CAB) protein technology. CAB therapies are designed to be active only upon specific conditions in the tumor micro-environment. Exuma, which has m...

HemaCare Corp HEMA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12102018] Prices from USD $250

SummaryHemaCare Corp HemaCare is a provider of biological blood products and services. The company offers primary blood cells and tissues derived from normal and mobilized peripheral blood, cord blood, and bone marrow. It spans its expertise in isolations, custom cell collections and testing of primary cells for research use. HemaCare offers apheresis collection services to industry and academic o...

Risk factors for cardiovascular disease closely track with changes in diet patterns

During the holiday season, it can be difficult for even the most determined of us to stick to a healthy diet. A piece of Halloween candy here, a pumpkin spice latte there, and suddenly we're left feeling like we forgot what vegetables taste like.

Precision medicine-based approach to slow or reverse biologic drivers of Alzheimer's disease

Alzheimer's disease is a progressive, neurodegenerative condition in which individuals exhibit memory loss, dementia, and impaired metabolism.

Neural networks and supervised machine learning techniques can efficiently characterize cells that have been studied using single cell RNA-sequencing: http://ow.ly/xgoH30mBnMe 

Neural networks and supervised machine learning techniques can efficiently characterize cells that have been studied using single cell RNA-sequencing: http://ow.ly/xgoH30mBnMe 

$LLY $ARMO Interesting new paper of peg-IL10 in @Cancer_Cell https://www.cell.com/cancer-cell/pdfExtended/S1535-6108(18)30473-2 … Randomized data of peg-IL10+PD1 vs PD1 alone in 1L/2L NSCLC will be next big test for I/O combo w/ a novel MoA https://c

$LLY $ARMO Interesting new paper of peg-IL10 in @Cancer_Cell https://www.cell.com/cancer-cell/pdfExtended/S1535-6108(18)30473-2 … Randomized data of peg-IL10+PD1 vs PD1 alone in 1L/2L NSCLC will be next big test for I/O combo w/ a novel MoA https://clinicaltrials.gov/ct2/show/NCT03382899 … Meanwhile

K2 Energy Solutions Expands their Competitive Cell Portfolio

HENDERSON, Nev., Nov. 13, 2018 /PRNewswire/ -- K2 Energy has expanded their cell offering portfolio due to aggressive growth. Even as their Power and Energy Read more...

Researchers find inhibiting one protein destroys toxic clumps seen in Parkinson's disease

(Georgetown University Medical Center) A team of neurologists at Georgetown University Medical Center has found that inhibiting the USP13 molecule may be a therapeutic target in Parkinson's disease and other similar forms of neurodegeneration.

Two-handed handshake that encourages cell suicide

Researchers have discovered a mechanism that eliminates T cells that pose autoimmune dangers. Although the mechanisms are intertwined with biochemical processes, they also work mechanically, grasping, tugging and clamping, according to Georgia Institute of Technology researchers, who measured responses to physical force acting on these elimination mechanisms. The mechanisms' purpose is to make d...

Nightstar Provides Business Update and Q3 Financial Results

A big announcement for these trials will be the initiation of the Phase 2/3 expansion study for the candidate NSR-RPGR for X-linked retinitis pigmentosa (XLRP), which is a genetic eye disease. The post Nightstar Provides Business Update and Q3 Financial Results appeared first on Investing News Network.

Ulcers Global Clinical Trials Review, H2, 2018 [Report Updated: 28092018] Prices from USD $2500

Ulcers Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report, Ulcers Global Clinical Trials Review, H2, 2018" provides an overview of Ulcers clinical trials scenario. This report provides top line data relating to the clinical trials on Ulcers. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The repor...

One Health Brings Together Different Health Sectors to Fight Antibiotic Resistance

In this clip, Debra Goff, PharmD, FCCP, infectious disease clinical pharmacist and Associate Professor at The Ohio State University, tells Pharmacy Times about One Health, a movement dedicated to bringing together different fields that handle antibiotics to prevent the misuse of these bacteria-killing drugs. 


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks